In recent years, many FXR agonists have been studied in animal experiments and clinical trials (Fiorucci et al., 2012; Sepe et al., 2015), among which obeticholic acid (OCA) has been successfully approved by U S Food and Drug Administration (FDA) to treat patients with PBC (Kowdley et al., 2018). This evidence concerns the gene NR1H4 and primary biliary cholangitis.